PIPERACILLIN AND TAZOBACTAM FOR INJECTION 3 G — DIN 02299631
PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G · SANDOZ CANADA INCORPORATED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION?
PIPERACILLIN AND TAZOBACTAM FOR INJECTION 3 G contains PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G. It is listed in the Health Canada Drug Product Database under DIN 02299631, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 22-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION used for?
Piperacillin and Tazobactam for Injection is indicated for the treatment of patients with systemic and/or local bacterial infections, caused by piperacillin resistant, piperacillin/tazobactam susceptible, ß-lactamase producing strains of designated microorganisms. These include intra-abdominal infections, skin and skin structure infections, gynecological infections, community-acquired lower respiratory tract infections, and nosocomial pneumonia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Piperacillin And Beta-Lactamase Inhibitor cost around the world?
Piperacillin And Beta-Lactamase Inhibitor is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Romania publishes a max producer price; Saudi Arabia publishes a public; South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 13 | 15 | SAR███.██ |
| South Africa | single exit price | 13 | 15 | ZAR███.██ |
| Romania | max producer price | 4 | 6 | RON███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
38 pack listings across 32 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Piperacillin And Beta-Lactamase Inhibitor pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Piperacillin And Beta-Lactamase Inhibitor in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Piperacillin And Beta-Lactamase Inhibitor, across 52 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 5 | 5 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| STERIMAX INC | 5 | 5 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| AURO PHARMA INC | 5 | 3 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| EUGIA PHARMA INC. | 5 | 3 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | Sourceable in Canada |
| VPI PHARMACEUTICALS INC | 5 | 0 | VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| APOTEX INC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| HIKMA CANADA LIMITED | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| LEDERLE CYANAMID CANADA INC. | 3 | 0 | TAZOCIN PWS IV 2G PIPERACILLIN-.25G TAZOBAC., TAZOCIN PWS IV 3G PIPERACILLIN-.375G TAZOBAC, TAZOCIN PWS IV 4G PIPERACILLIN-.5G TAZOBAC. | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 3 | 0 | PIPERACILLIN AND TAZOBACTAM FOR INJECTION | No marketed DIN |
| PFIZER CANADA ULC | 3 | 0 | TAZOCIN | No marketed DIN |
| PHARMA STRIDES CANADA CORPORATION | 3 | 0 | PIPERACILLIN/TAZOBACTAM FOR INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 2 g / 0.25 g, 3 g / 0.375 g, 4 g / 0.5 g, 12 g / 1.5 g, 36 g / 4.5 g per vial |
| Storage | 20-25ºC (room temperature) and 2-8ºC (refrigerated temperature). Discard unused portions after storage for 24 hours at room temperature or 48 hours when refrigerated. Intravenous admixtures are usually recommended for use within a maximum of 24 hours at room temperature or 72 hours when refrigerated (2-8°C). Stability studies in glass vials with Lactated Ringer’s Injection show chemical stability for up to 24 hours at room temperature (20-25ºC) and up to 72 hours at refrigerated temperatures (2-8ºC). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Piperacillin And Beta-Lactamase Inhibitor |
|---|---|
| ATC code | J01CR05 |
| AHFS class | 08:12.16.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02299631 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2299631 |
| Brand name | PIPERACILLIN AND TAZOBACTAM FOR INJECTION |
| Generic / active ingredient | PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | J01CR05 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01CR |
| Current status | MARKETED |
| Status date | 22-Oct-2021 |
| Original market date | 2007-11-05 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Piperacillin And Beta-Lactamase Inhibitor in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for PIPERACILLIN AND TAZOBACTAM FOR INJECTION
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
16 of 52 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02402068 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02402076 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3.000 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362627 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 12 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02377748 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 1.5 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02330547 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02299623 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 4 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02299658 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2.00 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362619 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.5 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | 02362635 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 4 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | 02402084 |
2 · Same class — other molecules in ATC J01CR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Amoxicillin And Beta-Lactamase Inhibitor | AG-AMOXI CLAV · AG-AMOXI CLAV SUSPENSION · AMOXI-CLAV · AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION · AMOXICILLIN/CLAV · APO-AMOXI CLAV · APO-AMOXI CLAV 125MG/31.25MG PER 5ML · APO-AMOXI CLAV 250MG/62.5MG PER 5ML · APO-AMOXICILLIN-CLAVULANATE · AURO-AMOXICLAV · CLAVULIN 125 F ORAL SUS · CLAVULIN 200 · CLAVULIN 250 F ORAL SUS · CLAVULIN 250 TAB · CLAVULIN 400 · CLAVULIN 500 F TAB · CLAVULIN 875 · JAMP AMOXI CLAV · JAMP AMOXI CLAV SUSPENSION · M-AMOXI CLAV · MINT-AMOXI/CLAV · NOVO-CLAVAMOXIN 125 · NOVO-CLAVAMOXIN 250 · NOVO-CLAVAMOXIN 875 · PMS-AMCLAV-200 · PMS-AMCLAV-400 · PMS-AMCLAV-875 · PRO-AMOXI CLAV · RATIO-ACLAVULANATE · RATIO-ACLAVULANATE 125 F · RATIO-ACLAVULANATE 250 F · SANDOZ AMOXI-CLAV TABLET | 59 | 28 | Yes |
| Piperacillin And Beta-Lactamase Inhibitor | JAMP-PIP/TAZ · PIPERACILLIN / TAZOBACTAM POWDER FOR INJECTION · PIPERACILLIN AND TAZOBACTAM FOR INJECTION · PIPERACILLIN/TAZOBACTAM FOR INJECTION · TAZOCIN · TAZOCIN PWS IV 2G PIPERACILLIN-.25G TAZOBAC. · TAZOCIN PWS IV 3G PIPERACILLIN-.375G TAZOBAC · TAZOCIN PWS IV 4G PIPERACILLIN-.5G TAZOBAC. · VPI-PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 52 | 16 | Yes |
| Ticarcillin And Beta-Lactamase Inhibitor | TIMENTIN | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01CA | Amoxicillin · Ampicillin · Ampicillin, Combinations · Bacampicillin · Piperacillin · Pivampicillin · Pivmecillinam · Ticarcillin | 201 | 47 |
| J01CF | Beta-Lactamase Resistant Penicillins · Cloxacillin · Flucloxacillin | 42 | 9 |
| J01CE | Benzathine Benzylpenicillin · Benzathine Phenoxymethylpenicillin · Benzylpenicillin · Combinations · Phenoxymethylpenicillin · Procaine Penicillin | 69 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PIPERACILLIN AND TAZOBACTAM FOR INJECTION called?
The same molecule, Piperacillin And Beta-Lactamase Inhibitor, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Pipractam | Latin | Saudi Arabia |
| Tazopip | Latin | South Africa |
| Tapranem | Latin | South Africa |
| Tazobax | Latin | South Africa |
| Tazogen | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.